Charles River Laboratories | CRL - Assets


Charles River Laboratories reported $7.45B in Assets for its fiscal quarter ending in September of 2026.





Assets Change Date
Agilent USD 13.97B 902M Jun/2026
Align Technology USD 6.52B 103.03M Sep/2026
Bio-Rad Laboratories USD 10.78B 531.1M Sep/2026
Bruker USD 5.83B 224.6M Sep/2026
Cardinal Health USD 59.54B 2.24B Sep/2026
Charles River Laboratories USD 7.45B 80.64M Sep/2026
Cigna USD 157.64B 562M Sep/2026
Concord Medical Services Hldg CNY 6.55B 186.1M Dec/2025
CVS Health USD 258.08B 4.31B Sep/2026
Danaher USD 93.28B 914M Sep/2026
Dentsply International USD 5.19B 14M Sep/2026
Elevance Health USD 127.8B 1.36B Sep/2026
Humana USD 57.28B 89M Sep/2026
Illumina USD 6.81B 162M Sep/2026
Incyte USD 7.29B 585.39M Sep/2026
Intrexon USD 73.16M 77.88M Jun/2024
IQVIA Holdings USD 30.47B 593M Sep/2026
Laboratory Of America USD 18.92B 392.3M Sep/2026
Lakefront Biotherapeutics EUR 3.35B 21.24M Jun/2026
Lonza CHF 18.97B 164M Dec/2025
McKesson USD 92.32B 3.99B Sep/2026
Merck EUR 52.69B 383M Jun/2026
Mettler Toledo International USD 3.7B 24.53M Sep/2026
Novartis USD 117.15B 4.88B Sep/2026
Pfizer USD 204.54B 3.41B Sep/2026
Quest Diagnostics USD 17.22B 282M Sep/2026
Revvity USD 11.49B 555.49M Sep/2026
Thermo Fisher Scientific USD 114.23B 1.06B Sep/2026
United Therapeutics USD 7.03B 186M Sep/2026
UnitedHealth USD 312.78B 3.06B Sep/2026
Veradigm USD 1.5B 185.94M Dec/2022
Waters USD 24.12B 636M Sep/2026
West Pharmaceutical Services USD 4.06B 15.7M Sep/2026